Intervention	O
,	O
primary	O
and	O
secondary	O
endpoints	O

Patients	O
were	O
randomly	O
assigned	O
via	O
a	O
web	O
-	O
based	O
system	O
at	O
a	O
1	O
:	O
1	O
ratio	O
to	O
the	O
current	O
standard	O
of	O
care	O
at	O
each	O
hospital	O
with	O
or	O
without	O
the	O
addition	O
of	O
300ml	O
of	O
ConvP	O
,	O
the	O
standard	O
volume	O
of	O
one	O
plasma	O
unit	O
produced	O
by	O
Sanquin	O
Blood	O
Supply	O
,	O
was	O
administered	O
intravenously	O
on	O
the	O
day	O
of	O
inclusion	O
.	O

Patients	O
without	O
a	O
clinical	O
response	O
and	O
a	O
persistently	O
positive	O
RT	O
-	O
PCR	O
could	O
receive	O
a	O
second	O
plasma	O
unit	O
after	O
five	O
days	O
.	O

Off	O
-	O
label	O
use	O
of	O
EMA	O
-	O
approved	O
drugs	O
(	O
e	O
.	O
g	O
.	O
chloroquine	O
,	O
azithromycin	O
,	O
lopinavir	O
/	O
ritonavir	O
,	O
tocilizumab	O
,	O
anakinra	O
)	O
as	O
a	O
treatment	O
for	O
COVID	O
-	O
19	O
was	O
allowed	O
in	O
hospitals	O
were	O
this	O
was	O
part	O
of	O
the	O
standard	O
of	O
care	O
.	O

We	O
scored	O
the	O
clinical	B-OtherOutcome
status	I-OtherOutcome
with	I-OtherOutcome
the	I-OtherOutcome
ordinal	I-OtherOutcome
8	I-OtherOutcome
-	I-OtherOutcome
point	I-OtherOutcome
WHO	I-OtherOutcome
COVID	I-OtherOutcome
-	I-OtherOutcome
19	I-OtherOutcome
disease	I-OtherOutcome
severity	I-OtherOutcome
scale	I-OtherOutcome
on	B-TimeFrame
days	I-TimeFrame
1	I-TimeFrame
,	I-TimeFrame
15	I-TimeFrame
and	I-TimeFrame
30	I-TimeFrame
.	O

16	O
Serum	O
samples	O
and	O
nasopharyngeal	O
swabs	O
were	O
collected	O
at	O
inclusion	O
preceding	O
treatment	O
and	O
thereafter	O
.	O

The	O
primary	O
endpoint	O
of	O
the	O
study	O
was	O
overall	B-PrimaryOutcome
mortality	I-PrimaryOutcome
until	B-TimeFrame
discharge	I-TimeFrame
from	I-TimeFrame
the	I-TimeFrame
hospital	I-TimeFrame
or	I-TimeFrame
a	I-TimeFrame
maximum	I-TimeFrame
of	I-TimeFrame
60	I-TimeFrame
days	I-TimeFrame
after	I-TimeFrame
admission	I-TimeFrame
whichever	I-TimeFrame
came	I-TimeFrame
first	I-TimeFrame
.	O

Key	O
secondary	O
clinical	O
endpoint	O
we	O
describe	O
here	O
are	O
the	O
improvement	B-SecondaryOutcome
on	I-SecondaryOutcome
the	I-SecondaryOutcome
8	I-SecondaryOutcome
-	I-SecondaryOutcome
point	I-SecondaryOutcome
WHO	I-SecondaryOutcome
COVID	I-SecondaryOutcome
-	I-SecondaryOutcome
19	I-SecondaryOutcome
disease	I-SecondaryOutcome
severity	I-SecondaryOutcome
scale	I-SecondaryOutcome
from	B-TimeFrame
inclusion	I-TimeFrame
to	I-TimeFrame
day	I-TimeFrame
15	I-TimeFrame
,	O
hospital	B-SecondaryOutcome
length	I-SecondaryOutcome
of	I-SecondaryOutcome
stay	I-SecondaryOutcome
and	O
safety	B-SecondaryOutcome
.	O

